Joseph Robert Wagner

US Patent:

8354370, Jan 15, 2013

Filed:

Jun 16, 2008

Appl. No.:

12/140065

Inventors:

Gene Kopen - Wynnewood PA, US
Joseph Wagner - West Chester PA, US
Vanessa Ragaglia - Newtown Square PA, US
Baron Heimbach - Philadelphia PA, US
Richard S. Gore - West Chester PA, US

Assignee:

Garnet BioTherapeutics, Inc. - Malvern PA

International Classification:

A61K 38/00
A61K 38/37
A61K 38/22
A61K 38/18

US Classification:

514 11, 514 51, 514 53, 514 76, 514 212

Abstract:

The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.

US Patent:

8486696, Jul 16, 2013

Filed:

Feb 10, 2005

Appl. No.:

11/054824

Inventors:

Tony W. Ho - Berwyn PA, US
Gene C. Kopen - Wynnewood PA, US
William F. Righter - Ridley Park PA, US
J. Lynn Rutkowski - Wynnewood PA, US
Joseph Wagner - West Chester PA, US

Assignee:

Garnet BioTherapeutics, Inc. - Malvern PA

International Classification:

C12N 5/00

US Classification:

435374, 435325, 435366

Abstract:

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.

US Patent:

20030059414, Mar 27, 2003

Filed:

Sep 21, 2001

Appl. No.:

09/960244

Inventors:

Tony Ho - Berwyn PA, US
Gene Kopen - Wynnewood PA, US
William Righter - Ridley Park PA, US
J. Rutkowski - Wynnewood PA, US
Joseph Wagner - West Chester PA, US

International Classification:

A61K048/00
C12N005/08

US Classification:

424/093210, 435/368000, 435/366000

Abstract:

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.

US Patent:

20040058412, Mar 25, 2004

Filed:

Sep 20, 2002

Appl. No.:

10/251685

Inventors:

Tony Ho - Berwyn PA, US
Gene Kopen - Wynnewood PA, US
William Righter - Ridley Park PA, US
J. Rutkowski - Wynnewood PA, US
Joseph Wagner - West Chester PA, US
W. Herring - Valley Forge PA, US
Vanessa Ragaglia - Newtown Square PA, US

Assignee:

Neuronyx, Inc.

International Classification:

C12N005/08
C12P021/02
A61K045/00

US Classification:

435/069100, 435/366000, 435/320100, 435/325000, 424/093700

Abstract:

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and to formulate pharmaceutical compositions. In a further embodiment, a substantially homogenous populaton of cells which co-express CD49c, CD90 and at least one cardiac-related transcription factor is made and can be used to treat a human suffering from a cardiac condition.

US Patent:

20060233771, Oct 19, 2006

Filed:

Sep 24, 2003

Appl. No.:

10/529097

Inventors:

Ernesto Arenas - Stockholm, SE
Joseph Wagner - West Chester PA, US
Goncalo Branco - Stockholm, SE
Kyle Sousa - Stockholm, SE

International Classification:

A61K 48/00
C12N 5/08
C12N 15/09

US Classification:

424093210, 435455000, 435325000, 435368000, 514044000

Abstract:

Methods for promoting dopaminergic neuronal development and producing neural cells having a dopaminergic phenotype are provided. Dopaminergic neural cells may be used for treating individuals having a neurodegenerative disease such as Parkinson's disease. Dopaminergic cells may be implanted into the brain of the individual, and/or dopaminergic neural development may be induced or enhanced in the brain of the individual. Methods comprise expressing a nuclear receptor of the NG4A subfamily, e.g., Nurr1, above basal levels within the cell and treating the cell with Wnt ligand, thereby producing or enhancing proliferation, self-renewal, survival and/or dopaminergic induction, differentiation, survival or acquisition of a neuronal dopaminergic phenotype. The cell may be co-cultured with astrocytes or glial cells and may be contacted with an FGF growth factor.

US Patent:

20070224177, Sep 27, 2007

Filed:

Feb 7, 2007

Appl. No.:

11/703479

Inventors:

Tony Ho - Berwyn PA, US
Gene Kopen - Wynnewood PA, US
William Righter - Ridley Park PA, US
J. Rutkowski - Bryn Mawr PA, US
Joseph Wagner - West Chester PA, US
W. Herring - Valley Forge PA, US
Vanessa Ragaglia - Newtown Square PA, US

International Classification:

A61K 48/00

US Classification:

424093210

Abstract:

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and to formulate pharmaceutical compositions. In a further embodiment, a substantially homogenous population of cells which co-express CD49c, CD90 and at least one cardiac-related transcription factor is made and can be used to treat a human suffering from a cardiac condition.

US Patent:

20070231309, Oct 4, 2007

Filed:

Mar 19, 2007

Appl. No.:

11/723348

Inventors:

Tony Ho - Berwyn PA, US
Gene Kopen - Wynnewood PA, US
William Righter - Ridley Park PA, US
J. Rutkowski - Wynnewood PA, US
Joseph Wagner - West Chester PA, US

Assignee:

Neuronyx, Inc. - Malvern PA

International Classification:

A61K 48/00

US Classification:

424093210, 424093700

Abstract:

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury cardiac or neurological condition and formulate pharmaceutical compositions.

US Patent:

20070243609, Oct 18, 2007

Filed:

Feb 7, 2007

Appl. No.:

11/703513

Inventors:

Tony Ho - Berwyn PA, US
Gene Kopen - Wynnewood PA, US
William Righter - Ridley Park PA, US
J. Rutkowski - Bryn Mawr PA, US
Joseph Wagner - West Chester PA, US

International Classification:

C12N 5/06

US Classification:

435326000, 435325000

Abstract:

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.